Winzac Capital

Winzac Capital is a venture capital firm established in 2013 and located in Shenzhen, China. The firm specializes in investing in a variety of sectors, including advanced manufacturing, biomedicine, and the Internet of Things. Through its strategic investments, Winzac Capital aims to support innovative companies and contribute to technological advancements in these fields.

Jin Wang

Partner and President

Qiangbo Xiong

President

2 past transactions

InkBank

Venture Round in 2022
InkBank is an inkjet ink research and development company. The business offers clients individualized customization and flexible production options for new environmentally friendly inkjet printing, digital printing, nano-new materials for digital printing, packaging printing, office inkjet printing, and other industries.

Sinogen Biopharma

Series A in 2022
Sinogen Biopharma is a biotechnology company dedicated to connecting China's innovative drug development with the pharmaceutical market in the United States. The company specializes in the licensing and development of bacterial carrier-based biological anti-tumor drugs aimed at treating malignant tumors, particularly in the area of metastatic tumors and rare diseases. By focusing on the creation of innovative anti-cancer therapies, Sinogen Biopharma seeks to address the needs of both domestic and international pharmaceutical markets.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.